Latest Breaking News On - Xiia fxiia - Page 2 : comparemela.com

First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - Additional Sebetralstat data also presented - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage

Xiia fxiiaEdward feenerJarrod aldomSally hamptonAndrew crockettExchange commissionDevelopment officerKalvista pharmaceuticals incVp researchCorporate communicationsVista pharmaceuticalsChief executive officerKallikrein kinin systemKinin systemChief scientific officerOral inhibitors